Quince Therapeutics, Inc. (IRLA) Operating income 2018–2025
Quince Therapeutics, Inc. (IRLA) annual operating income history from SEC filings — each fiscal year as reported.
-$58.1MFY2025 · since FY2018: -$12.1M → -$58.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$58.1M | -1.4% |
| FY2024 | -$57.3M | -65.5% |
| FY2023 | -$34.6M | +33.4% |
| FY2022 | -$52.0M | +42.4% |
| FY2021 | -$90.3M | -14.5% |
| FY2020 | -$78.9M | -101.4% |
| FY2019 | -$39.2M | -223.2% |
| FY2018 | -$12.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IRLA financial trends
IRLA RevenueIRLA Net incomeIRLA Net marginIRLA Gross profitIRLA Gross marginIRLA Operating marginIRLA Operating cash flowIRLA Free cash flowIRLA Capital expendituresIRLA Return on equityIRLA Stock buybacksIRLA Dividends paidIRLA Total assetsIRLA Total liabilitiesIRLA Shareholders’ equityIRLA overview →